Recent discussions on X about United Therapeutics (UTHR) have been buzzing with excitement following the release of positive Phase 3 clinical trial data for Tyvaso in treating Idiopathic Pulmonary Fibrosis (IPF). Many users are highlighting the stock's remarkable surge of over 30% in a single day, attributing this to the unexpected success of the TETON-2 study, which some had anticipated would fail. The news has sparked conversations about the potential for Tyvaso to shift treatment paradigms in the rare lung disease space.
Analyst upgrades and raised price targets have further fueled the optimism on the platform, with several posts pointing to confidence from major financial institutions in the company's future growth. There's a palpable sense of surprise and enthusiasm among discussants, as the successful trial results could open new market opportunities for United Therapeutics. However, some caution that sustaining this momentum will depend on regulatory approvals and further clinical outcomes.
Note: This discussion summary was generated from an AI condensation of post data.
United Therapeutics Congressional Stock Trading
Members of Congress have traded $UTHR stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $UTHR stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 06/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
United Therapeutics Insider Trading Activity
United Therapeutics insiders have traded $UTHR stock on the open market 95 times in the past 6 months. Of those trades, 0 have been purchases and 95 have been sales.
Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:
- PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 66 sales selling 121,000 shares for an estimated $36,089,724.
- JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 5 sales selling 12,000 shares for an estimated $3,904,496.
- RAYMOND DWEK has made 0 purchases and 3 sales selling 10,000 shares for an estimated $2,850,390.
- TOMMY G THOMPSON has made 0 purchases and 2 sales selling 5,000 shares for an estimated $1,559,855.
- CHRISTOPHER PATUSKY has made 0 purchases and 7 sales selling 5,000 shares for an estimated $1,553,584.
- CHRISTOPHER CAUSEY has made 0 purchases and 3 sales selling 3,000 shares for an estimated $1,269,630.
- RICHARD GILTNER sold 3,036 shares for an estimated $879,214
- MICHAEL BENKOWITZ (PRESIDENT AND COO) has made 0 purchases and 7 sales selling 2,000 shares for an estimated $640,183.
- NILDA MESA sold 645 shares for an estimated $187,045
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
United Therapeutics Hedge Fund Activity
We have seen 350 institutional investors add shares of United Therapeutics stock to their portfolio, and 355 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 720,363 shares (-62.9%) from their portfolio in Q2 2025, for an estimated $206,996,308
- WELLINGTON MANAGEMENT GROUP LLP removed 583,480 shares (-28.8%) from their portfolio in Q2 2025, for an estimated $167,662,978
- DEERFIELD MANAGEMENT COMPANY, L.P. added 540,626 shares (+inf%) to their portfolio in Q2 2025, for an estimated $155,348,881
- INVESCO LTD. added 419,588 shares (+90.2%) to their portfolio in Q2 2025, for an estimated $120,568,611
- AQR CAPITAL MANAGEMENT LLC added 364,713 shares (+40.1%) to their portfolio in Q2 2025, for an estimated $104,800,280
- VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. removed 328,783 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $94,475,795
- AVORO CAPITAL ADVISORS LLC removed 305,000 shares (-11.4%) from their portfolio in Q2 2025, for an estimated $87,641,750
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
United Therapeutics Government Contracts
We have seen $984,765 of award payments to $UTHR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BULK ORDER TYVASO: $89,934
- BULK PHARMACY TYVASO: $88,161
- OPSUMIT 10MG-QTY 4 @ $6,270.03 ADEMPAS 1MG, QTY 1 @ $12,153.05 REMODULIN 5MG/ML INJ 20ML VIAL, QTY 1 @ $6,2...: $49,773
- OPSUMIT 10MG-QTY 2 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 JULY 2025: $37,233
- OPSUMIT 10MG-QTY 4 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 SEPT FY25: $37,233
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
United Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $UTHR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 09/02/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/31/2025
- UBS issued a "Buy" rating on 06/30/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/02/2025
- JP Morgan issued a "Overweight" rating on 05/01/2025
To track analyst ratings and price targets for United Therapeutics, check out Quiver Quantitative's $UTHR forecast page.
United Therapeutics Price Targets
Multiple analysts have issued price targets for $UTHR recently. We have seen 8 analysts offer price targets for $UTHR in the last 6 months, with a median target of $402.5.
Here are some recent targets:
- Greg Harrison from B of A Securities set a target price of $463.0 on 09/02/2025
- Roger Song from Jefferies set a target price of $564.0 on 09/02/2025
- Ashwani Verma from UBS set a target price of $415.0 on 08/13/2025
- Tiago Fauth from Wells Fargo set a target price of $295.0 on 07/31/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $400.0 on 07/31/2025
- Terence Flynn from Morgan Stanley set a target price of $328.0 on 07/10/2025
- Jessica Fye from JP Morgan set a target price of $330.0 on 07/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
